Issues associated with Aromatase Inhibitor–Associated Musculoskeletal Symptoms in Breast Cancer

Abstract

Since Aromatase inhibitors are the standard therapy in hormone receptor positive postmenopausal breast cancer females .What we are concerned is the related complications named Aromatase Inhibitor-associated musculoskeletal symptoms (AIMSS) such as arthralgia, osteoporosis, loss of bone mineral density or musculoskeletal pain which will lead to poor compliance of patients and treatment failure. The further understanding the role and mechanism of aromatase inhibitors will help dealing with the AIMSS. Meanwhile, how to measure or diagnose the AIMSS may need more consensuses because so far no definite marker can define the AIMSS and functional tests are most subjective report from patients. In clinical practice, some therapeutic trials have focused on the treatment of AIMSS but still no exclusive agreement. Accordingly, we review and highlight the related issues about AIMSS in breast cancer and hope for more comprehensive understanding about this issue then come up with the consensus.To cite this article: Tsai-Ju Chien. Issues associated with Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Breast Cancer. Musculoskelet Regen 2015; 2: e856.